Kempower Establishes a New Facility for EV Chargers to Meet Global e-Mobility Demand, Scales up Production by the End of 2022
1.7.2021 13:56:00 EEST | Business Wire | Press release
Kemppi Group Oy, the owner of Kempower Oy, acquires a business property managed by S-Bank Properties, including 10 300 m2 of factory space. The new facility will enable Kempower to scale up production by approximately 500% compared to its current capacity. Kempower will gradually ramp up production in 2021-2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005423/en/
Kempower establishes a new facility for EV chargers. Photo by Kempower. (Photo: Business Wire)
Kempower, a leading e-mobility charging technology provider in the Nordics, responds to the rapidly growing e-mobility market demand by scaling up production gradually by the end of 2022. Kemppi Group Oy, the owner of Kempower Oy, acquires a business property including 10 300 m2 of factory space. The business property includes extensive unused building right to further expand production in the future. The seller in the transaction is the insurance group Fennia, for which S-Bank's subsidiary S-Bank Properties Ltd provides real estate portfolio management and administration services.
The factory, originally built in 2007 and expanded in 2020, is located in Rälssinkatu 1, Lahti, Finland, with excellent transport connections. Kemppi Group will lease the factory to Kempower. The new facility will enable Kempower to expand its production by approximately 500% compared to the current capacity. Kempower’s production will be scaled up for the second time in a short time: at the beginning of 2021, Kempower increased its production by five times from the 2020 level.
“As Kempower’s owners, we are very committed to the company. Kempower has a lot of growth potential and the international EV charging market has reacted positively to Kempower’s DC charging offering. With this investment, we want to ensure Kempower’s ability to respond to the market demand”, states Antti Kemppi, Chairman of the Board of Kemppi Group & Kempower.
”We are particularly pleased to be able to continue the life of this valuable business property and to provide new jobs in the Lahti region”, Antti Kemppi adds.
“It’s great that this well-kept property found a new home. I believe that the site's modern production facilities offer a great platform to develop business in the future” says Harri Oravainen, Real Estate Investment Director, S-Bank Properties.
“Our aim is to be the preferred partner in the world in developing emission-free business. Our ultimate goal is to create an EV charging infrastructure so extensive and reliable, that the electric vehicles can and will be the new reality. With the new facility, we are able to support our customers in developing emission-free business even faster than before”, states Tomi Ristimäki, CEO, Kempower.
“In the new facility, Kempower will have all the essential functions in one location, including production, R&D, laboratory, testing and offices. The new facility will allow us to be efficient and agile as all the teams will be working seamlessly under one roof”, says Tomi Ristimäki, CEO, Kempower.
The preparations for Kempower’s new facility will start immediately. To ensure customer deliveries, Kempower will gradually ramp up production in 2021-2022. All company functions will be moved to the new location by the end of 2022.
Catella Asset Management acted as Kemppi Groups’ buyside advisor and HPP Attorneys as legal advisors on the transaction.
Kempower designs and manufactures DC fast charging solutions for electric vehicles and machines operating in the most demanding conditions. We are a largescale charging system supplier, aiming for a smoothly running electric mobility infrastructure. With 70 years of experience in perfecting power sources, we set the bar high in engineering and user-experience design. Over 90% of our materials & components are sourced from Finland. Kempower DC charging solutions are designed and manufactured in Lahti, Finland, and available globally. www.kempower.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005423/en/
Contact information
For more information, please contact:
Tomi Ristimäki
CEO
Kempower Oy
tomi.ristimaki@kempower.com
+358 44 289 9815
Kempower media contacts
Paula Savonen
Marketing & Communications manager
paula.savonen@kempower.com
+358 400 343 851
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom